<!doctype html public "-//W3C//DTD W3 HTML//EN">
<html><head><style type="text/css"><!--
blockquote, dl, ul, ol, li { margin-top: 0 ; margin-bottom: 0 }
--></style><title>Fwd: 2003-2004 EMBS-BMES Distinguished Lecture
Series-</title></head><body>
<blockquote type="cite" cite><br>
Dear colleagues and friends,<br>
<br>
The Boston chapter of the Institute of Electrical and Electronics
Engineers<br>
(IEEE)-Engineering in
Medicine and Biology Society (EMBS)<br>
<span
></span
> <span
></span>
&<br>
<span
></span> the MIT Biomedical Engineering Society (BMES)<br>
<span
></span
> <span
></span> proudly present:<br>
<br>
*** The 2003-2004 EMBS-BMES
Distinguished Lecture Series ***<br>
<br>
We invite you to join us for our new monthly lecture series in which
we explore<br>
recent developments and stimulating topics in the expanding field of
biomedical<br>
engineering. In the spring, speakers from both academia and
industry will introduce such<br>
subjects as genes, genomics, proteomics, and systems biology.<br>
<br>
Our sixth lecture will be:<br>
<br>
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<br>
<font face="Arial" color="#000080"><b>The Drug Discovery Process: An
Industrial Perspective</b></font><font face="Arial"><br>
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<br>
<br>
W. Stephen Faraci, Senior Director, Discovery Technology Center<br>
Pfizer Global R & D, Cambridge, MA<br>
<br>
Tuesday, February 17, 2004<br>
7PM (Refreshments at 6:30PM)<br>
MIT Building 66, 25 Ames Street, Room 66-110<br>
(For directions to MIT, please visit<font color="#0000FF"><u>
http://whereis.mit.edu</u></font>)<br>
<br>
* This event is free and open to the public.*<br>
<br>
*********************************************************************<span
></span>***<br>
<br>
ABSTRACT:<br>
<br>
The drug discovery process is a long and costly process, taking over
15 years from idea generation to approved drug and costing almost 1
billion dollars. There are many reasons for this, including long-term
safety studies, complex regulatory issues and the high level of
attrition of drugs entering preclinical and clinical development. This
talk will focus on the drug discovery process, from target
identification to IND filing to NDA submission. New technologies that
can aid in this process and help reduce the attrition currently
observed in the industry will be discussed.<br>
<br>
SPEAKER BACKGROUND:<br>
<br>
W. Stephen Faraci, PhD, is Senior Director and Head, Biology as well
as Interim Site Head at the Discovery Technology Center (DTC) in
Cambridge, Massachusetts—which is a part of Pfizer’s Global
Research and Development division. Steve received his PhD in Chemistry
from Wesleyan University in 1986 and did postdoctoral research with
Professor Christopher Walsh at MIT from 1986 – 1988. He joined
Pfizer Central Research in Groton, CT in 1988 as a Research Scientist
in the New Leads Department, which was pioneering the use of high
throughput screening. In 1999, he relocated to the DTC in Cambridge,
MA as Pfizer opened a new site in the Boston area. The goal of the DTC
is to improve the efficiency of the drug discovery paradigm. This goal
is being approached through the integration of new technologies to
enable high speed screening of genome-derived targets for new drug
candidates and the evaluation of a new discovery paradigm based on
gene families as well as strategies to rapidly synthesize compounds
using parallel methodologies in order to profile these leads across a
wide-range of biological endpoints.<br>
<br>
*********************************************************************<span
></span>***<br>
<br>
</font>If you have any questions, please do not hesitate to contact
us. We look<br>
forward to seeing you!<br>
<br>
<br>
Best Regards,<br>
<br>
Mandy Yeung<x-tab>
</x-tab><x-tab>
</x-tab><x-tab>
</x-tab><x-tab>
</x-tab><x-tab>
</x-tab>Alexis DeSieno<br>
VP of Special Programs<x-tab>
</x-tab><x-tab>
</x-tab><x-tab>
</x-tab>President<br>
BMES,MIT Chapter<x-tab>
</x-tab><x-tab>
</x-tab><x-tab>
</x-tab><x-tab>
</x-tab>BMES, MIT Chapter<br>
mandyy@mit.edu<x-tab>
</x-tab><x-tab>
</x-tab><x-tab>
</x-tab><x-tab>
</x-tab>alexisd@mit.edu</blockquote>
<div><br></div>
</body>
</html>